Search

Molecular Hematopoiesis Workshop

The Molecular Hematopoiesis Workshop at the EHA2024 Hybrid Congress is back!

OrganizersChair: Michael Milsom (Germany)
Co-chairs: Kim De Keersmaecker (Belgium), Elisa Laurenti (United Kingdom) & Britta Will (United States)

The full workshop program is available below
Session 1: Signalling and metabolism
Session 2: Gene regulation
Session…

Read more

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

Read more

EU calls for proposal 2023

IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.

Read more

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

EU Calls for Proposal 2022

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

EU Calls for proposal 2021

Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more